This randomized controlled trial evaluates whether perioperative intravenous lidocaine infusion, combined with port-site ropivacaine infiltration, improves postoperative recovery after laparoscopic abdominal surgery. Participants will be assigned 1:1 to receive either intravenous lidocaine during surgery plus ropivacaine infiltration at surgical closure, or ropivacaine infiltration alone. The primary endpoint is postoperative quality of recovery measured by the QoR-15 questionnaire. Secondary endpoints include postoperative pain and opioid consumption, as well as plasma lidocaine and ropivacaine concentrations to assess systemic exposure and safety.
Patient undergoing scheduled colorectal cancer surgery via laparoscopy.
Patient aged 18 years or older.
Informed consent obtained and signed.
Affiliation to a social security system.
Allergy or contraindication to lidocaine or ropivacaine.
Allergy or contraindication to paracetamol, nefopam ketamine, propofol, dexamethasone, sufentanil, Celebrex or parecoxib, morphine derivatives, and colorectal surgery by laparotomy
Colorectal surgery with a non-cancerous indication.
Chronic preoperative pain (defined as persistent pain for more than 3 months).